Dr Athina Giannoudis BSc, MSc, PhD

Lecturer School of Dentistry

Work email A.Giannoudis@liverpool.ac.uk

Publications

Selected Publications

The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia (Journal article - 2013)
Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors (Journal article - 2011)
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia (Journal article - 2008)
Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression (Journal article - 2022)
The role of CPT1A as a biomarker of breast cancer progression: a bioinformatic approach (Journal article - 2022)
Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival (Journal article - 2021)
A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival (Journal article - 2019)
Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process (Journal article - 2018)
Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases (Conference Paper - 2017)
The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia (Journal article - 2014)

Filter the publication list

Filter list by type

Show all
Journal article
Conference paper
Chapter
Other

2024

A Bioinformatic Characterisation of the Glyolytic Enzyme ENO1 as a Biomarker of Breast Cancer Progression (Preprint)

DOI: 10.21203/rs.3.rs-3853453/v1

2023

ENO1 as a biomarker of breast cancer progression and metastasis – a bioinformatic approach (Preprint)

DOI: 10.1101/2023.11.01.23297919

Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases (Conference Paper)

Giannoudis, A., Sokol, E., Ramkissoon, S., Bhogal, T., Ross, J., McGregor, K., . . . Palmieri, C. (2023). Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases. In CANCER RESEARCH Vol. 83. doi:10.1158/1538-7445.SABCS22-P5-14-10

DOI: 10.1158/1538-7445.SABCS22-P5-14-10

Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors (Preprint)

DOI: 10.21203/rs.3.rs-2484456/v1

2022

Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression (Journal article)

Giannoudis, A., Vareslija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P. S., . . . Palmieri, C. (2022). Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO OPEN, 7(6). doi:10.1016/j.esmoop.2022.100636

DOI: 10.1016/j.esmoop.2022.100636

The role of CPT1A as a biomarker of breast cancer progression: a bioinformatic approach (Journal article)

Das, M., Giannoudis, A., & Sharma, V. (2022). The role of CPT1A as a biomarker of breast cancer progression: a bioinformatic approach. SCIENTIFIC REPORTS, 12(1). doi:10.1038/s41598-022-20585-x

DOI: 10.1038/s41598-022-20585-x

The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis (Conference Paper)

Giannoudis, A., Vareslija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P., . . . Palmieri, C. (2022). The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis. In ANNALS OF ONCOLOGY Vol. 33 (pp. S132). doi:10.1016/j.annonc.2022.03.035

DOI: 10.1016/j.annonc.2022.03.035

Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases (Conference Paper)

Bhogal, T., Sokol, E., Ramkissoon, S., Giannoudis, A., McGregor, K., Clark, A., . . . Palmieri, C. (2022). Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases. In CANCER RESEARCH Vol. 82. doi:10.1158/1538-7445.SABCS21-P5-07-04

DOI: 10.1158/1538-7445.SABCS21-P5-07-04

Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors (Conference Paper)

Giannoudis, A., Sokol, E., Ramkissoon, S. H., Bhogal, T., McGregor, K., Clark, A., . . . Palmieri, C. (2022). Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors. In CANCER RESEARCH Vol. 82. doi:10.1158/1538-7445.SABCS21-PD4-09

DOI: 10.1158/1538-7445.SABCS21-PD4-09

The Role of CPT1A as a Biomarker of Breast Cancer Progression – A Bioinformatic Analysis (Preprint)

DOI: 10.21203/rs.3.rs-1260675/v2

The Role of CPT1A as a Biomarker of Breast Cancer Progression – a Bioinformatic Analysis (Preprint)

DOI: 10.21203/rs.3.rs-1260675/v1

2021

Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival (Journal article)

Giannoudis, A., Sartori, A., Eastoe, L., Zakaria, R., Charlton, C., Hickson, N., . . . Palmieri, C. (2021). Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival. BREAST CANCER RESEARCH AND TREATMENT, 190(2), 241-253. doi:10.1007/s10549-021-06364-8

DOI: 10.1007/s10549-021-06364-8

Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases (Journal article)

Huang, R. S. P., Haberberger, J., McGregor, K., Mata, D. A., Decker, B., Hiemenz, M. C., . . . Ramkissoon, S. H. (2021). Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. ONCOLOGIST, 26(10), 835-844. doi:10.1002/onco.13855

DOI: 10.1002/onco.13855

Genomic Profiling Using The UltraSEEK Panel Identifies Discordancy Between Paired Primary And Breast Cancer Brain Metastases And An Association With Brain Metastasis-Free Survival (Preprint)

DOI: 10.21203/rs.3.rs-377753/v1

1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells. (Journal article)

Pradubyat, N., Giannoudis, A., Elmetwali, T., Mahalapbutr, P., Palmieri, C., Mitrpant, C., & Ketchart, W. (2021). 1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells.. Planta Medica. doi:10.1055/a-1307-3997

DOI: 10.1055/a-1307-3997

The genomic landscape of breast cancer brain metastases: a systematic review. (Journal article)

Morgan, A. J., Giannoudis, A., & Palmieri, C. (2021). The genomic landscape of breast cancer brain metastases: a systematic review.. The Lancet. Oncology, 22(1), e7-e17. doi:10.1016/S1470-2045(20)30556-8

DOI: 10.1016/S1470-2045(20)30556-8

2020

Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer (Journal article)

Giannoudis, A., Malki, M. I., Rudraraju, B., Mohhamed, H., Menon, S., Liloglou, T., . . . Palmieri, C. (2020). Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. Breast Cancer Research, 22(1). doi:10.1186/s13058-020-01359-7

DOI: 10.1186/s13058-020-01359-7

A systematic review of the receptor status and genomic landscape of breast cancer brain metastases (Conference Paper)

Morgan, A. J., Giannoudis, A., & Palmieri, C. (2020). A systematic review of the receptor status and genomic landscape of breast cancer brain metastases. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P4-05-22

DOI: 10.1158/1538-7445.SABCS19-P4-05-22

The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer (Conference Paper)

Giannoudis, A., Malki, M. I., Mohammed, H., Rudraraju, B., Menon, S., Ali, S., . . . Palmieri, C. (2020). The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P6-04-18

DOI: 10.1158/1538-7445.SABCS19-P6-04-18

UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis (Conference Paper)

Giannoudis, A., Eastoe, L., Charlton, C., Hickson, N., Zakaria, R., Platt-Higgins, A., . . . Palmieri, C. (2020). UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P4-09-07

DOI: 10.1158/1538-7445.SABCS19-P4-09-07

2019

A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival (Journal article)

Giannoudis, A., Clarke, K., Zakaria, R., Vareslija, D., Farahani, M., Rainbow, L., . . . Palmieri, C. (2019). A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival. SCIENTIFIC REPORTS, 9. doi:10.1038/s41598-019-55084-z

DOI: 10.1038/s41598-019-55084-z

Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer (Conference Paper)

Giannoudis, A., Clarke, K., Zakaria, R., Vareslija, D., Farahani, M., Rainbow, L., . . . Palmieri, C. (2019). Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.SABCS18-P6-05-02

DOI: 10.1158/1538-7445.SABCS18-P6-05-02

2018

Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process (Journal article)

Dickens, D., Rädisch, S., Chiduza, G. N., Giannoudis, A., Cross, M. J., Malik, H., . . . Nies, A. T. (2018). Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. Molecular Pharmaceutics, 15(8), 3557-3572. doi:10.1021/acs.molpharmaceut.8b00547

DOI: 10.1021/acs.molpharmaceut.8b00547

2017

Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases (Conference Paper)

Giannoudis, A., Zakaria, R., Platt-Higgins, A., Syed, K. A. R., Ashton, K., Dawson, T., . . . Palmieri, C. (2017). Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases. In CANCER RESEARCH Vol. 77. doi:10.1158/1538-7445.SABCS16-P2-03-04

DOI: 10.1158/1538-7445.SABCS16-P2-03-04

2016

A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer (Conference Paper)

Palmieri, C., Rudraraju, B., Giannoudis, A., Moore, D., Shaw, J., Chan, S., . . . Abdel-Fatah, T. M. A. (2016). A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-P5-08-17

DOI: 10.1158/1538-7445.SABCS15-P5-08-17

2015

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib (Journal article)

Redaelli, S., Perini, P., Ceccon, M., Piazza, R., Rigolio, R., Mauri, M., . . . Gambacorti-Passerini, C. (2015). In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. JOURNAL OF HEMATOLOGY & ONCOLOGY, 8. doi:10.1186/s13045-015-0179-4

DOI: 10.1186/s13045-015-0179-4

C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia (Journal article)

Lucas, C., Harris, B., Giannoudis, A., & Clark, R. (2015). C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica, 100(05), e179-e182. doi:10.3324/haematol.2014.115691

DOI: 10.3324/haematol.2014.115691

2014

Dual Glutathione-S-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia (Journal article)

Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., . . . Clark, R. E. (2014). Dual Glutathione-S-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(6), 694-703. doi:10.1038/clpt.2014.176

DOI: 10.1038/clpt.2014.176

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. HAEMATOLOGICA, 99(11), 1710-1715. doi:10.3324/haematol.2013.101972

DOI: 10.3324/haematol.2013.101972

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer (Journal article)

Rudraraju, B., Droog, M., Abdel-Fatah, T. M. A., Zwart, W., Giannoudis, A., Malki, M. I., . . . Palmieri, C. (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 147(2), 295-309. doi:10.1007/s10549-014-3098-0

DOI: 10.1007/s10549-014-3098-0

Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia. Haematologica, epub, September 5th 2014.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer (Journal article)

Rudraraju, B., Droog, M., Abdel-Fatah, T. M., Zwart, W., Giannoudis, A., Malki, M. I., . . . Palmieri, C. (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Research and Treatment, 147(2), 295-309.

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia (Journal article)

Giannoudis, A., Davies, A., Harris, B., Lucas, C., Pirmohamed, M., & Clark, R. (2014). The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia, 28(6), 1360-1363. doi:10.1038/leu.2014.38

DOI: 10.1038/leu.2014.38

2013

Transport of gabapentin by LAT1 (SLC7A5) (Journal article)

Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Rädisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). Biochemical Pharmacology, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022

DOI: 10.1016/j.bcp.2013.03.022

Transport of gabapentin by LAT1 (SLC7A5) (Journal article)

Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Raedisch, S., . . . Pirmohamed, M. (2013). Transport of gabapentin by LAT1 (SLC7A5). BIOCHEMICAL PHARMACOLOGY, 85(11), 1672-1683. doi:10.1016/j.bcp.2013.03.022

DOI: 10.1016/j.bcp.2013.03.022

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia (Journal article)

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035

DOI: 10.1182/blood-2012-01-405035

10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML) (Conference Paper)

Lucas, C., Harrisl, R., Giannoudis, A., & Clark, R. (2013). 10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML). In HAEMATOLOGICA Vol. 98 (pp. 55). Retrieved from https://www.webofscience.com/

10058-f4 a small molecule c-myc inhibitor decreases CIP2A and reduces BCR-ABL-1 tyrosine kinase activity in chronic myeloid leukaemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., & Clark, R. E. (2013). 10058-f4 a small molecule c-myc inhibitor decreases CIP2A and reduces BCR-ABL-1 tyrosine kinase activity in chronic myeloid leukaemia. Haematologica, 98, S1.

TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS (Conference Paper)

Giannoudis, A., Davies, A., Harris, R., Lucas, C., Pirmohamed, M., & Clark, R. (2013). TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 400). Retrieved from https://www.webofscience.com/

The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia (Journal article)

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.

The hOCT1 substrate metformin does not alter imatinib, dasatinib or nilotinib uptake into CML cells at clinically relevant concentrations (Journal article)

Francis, S., Giannoudis, A., Pirmohamed, M., & Clark, R. E. (2013). The hOCT1 substrate metformin does not alter imatinib, dasatinib or nilotinib uptake into CML cells at clinically relevant concentrations. BRITISH JOURNAL OF HAEMATOLOGY, 161, 58-59. Retrieved from https://www.webofscience.com/

Transcript levels and copy number variation of the ABCC3 efflux transporter can predict clinical outcome in imatinib-treated chronic myeloid leukaemia patients (Journal article)

Giannoudis, A., Davies, A., Harris, R. J., Lucas, C. M., Pirmohamed, M., & Clark, R. E. (2013). Transcript levels and copy number variation of the ABCC3 efflux transporter can predict clinical outcome in imatinib-treated chronic myeloid leukaemia patients. Haematologica, 98, S1.

of gabapentin by LAT1 (SLC7A5) (Journal article)

Dickens, D., Webb, S. D., Antonyuk, S., Giannoudis, A., Owen, A., Radisch, S., . . . Pirmohamed, M. (2013). of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol, 85, 1672-1683.

2012

Lamotrigine is a substrate for OCT1 in brain endothelial cells (Journal article)

Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., . . . Pirmohamed, M. (2012). Lamotrigine is a substrate for OCT1 in brain endothelial cells. BIOCHEMICAL PHARMACOLOGY, 83(6), 805-814. doi:10.1016/j.bcp.2011.12.032

DOI: 10.1016/j.bcp.2011.12.032

DUAL GSTT1 AND GSTM1 GENE DELETIONS INCREASE THE RISK OF IMATINIB FAILURE IN CHRONIC MYELOID LEUKAEMIA (CML) (Conference Paper)

Davies, A., Giannoudis, A., Wang, L. H., Austin, G., Holyoake, T., Mueller, M., . . . Clark, R. (2012). DUAL GSTT1 AND GSTM1 GENE DELETIONS INCREASE THE RISK OF IMATINIB FAILURE IN CHRONIC MYELOID LEUKAEMIA (CML). In HAEMATOLOGICA Vol. 97 (pp. 207). Retrieved from https://www.webofscience.com/

Dual GSTT1 and GSTM1 gene deletions increase the risk of imatinib failure in chronic myeloid leukaemia (Journal article)

Davies, A., Giannoudis, A., Wang, L., Austin, G., Holyoake, T., Mueller, M., . . . Clark, R. E. (2012). Dual GSTT1 and GSTM1 gene deletions increase the risk of imatinib failure in chronic myeloid leukaemia. Haematologica, 97, S1.

IMATINIB, BUT NOT NILOTINIB, IS ACTIVELY TRANSPORTED BY SLCO1A2 IN CHRONIC MYELOID LEUKAEMIA CELLS (Conference Paper)

Francis, S., Giannoudis, A., Davies, A., Austin, G., Konig, J., Pirmohammed, M., & Clark, R. (2012). IMATINIB, BUT NOT NILOTINIB, IS ACTIVELY TRANSPORTED BY SLCO1A2 IN CHRONIC MYELOID LEUKAEMIA CELLS. In HAEMATOLOGICA Vol. 97 (pp. 211). Retrieved from https://www.webofscience.com/

Imatinib, but not nilotinib, is actively transported by SLCO1A2 in chronic myeloid leukaemia cells (Journal article)

Francis, S., Giannoudis, A., Davies, A., Austin, G., KÃ¶nig, J., Pirmohamed, M., & Clark, R. E. (2012). Imatinib, but not nilotinib, is actively transported by SLCO1A2 in chronic myeloid leukaemia cells. Haematologica, 97, S1.

Lamotrigine is a substrate for OCT1 in brain endothelial cells (Journal article)

Dickens, D., Owen, A., Alfirevic, A., Giannoudis, A., Davies, A., Weksler, B., . . . Pirmohamed, M. (2012). Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharm, 83, 805-814.

Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells (Journal article)

Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. EXPERIMENTAL HEMATOLOGY, 40(10), 811-819. doi:10.1016/j.exphem.2012.05.013

DOI: 10.1016/j.exphem.2012.05.013

Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia (Journal article)

Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia. Experimental Hematology, 40, 811-819.

2011

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011). Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. BLOOD, 117(24), 6660-6668. doi:10.1182/blood-2010-08-304477

DOI: 10.1182/blood-2010-08-304477

Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors (Journal article)

Muthana, M., Giannoudis, A., Scott, S. D., Fang, H. -Y., Coffelt, S. B., Morrow, F. J., . . . Maitland, N. J. (2011). Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. CANCER RESEARCH, 71(5), 1805-1815. doi:10.1158/0008-5472.CAN-10-2349

DOI: 10.1158/0008-5472.CAN-10-2349

Correlation of hOCT1 SNPs and clinical outcome in imatinib treated chronic myeloid leukaemia patients; functional significance of M420del and M408V (Conference Paper)

Giannoudis, A., Wang, L., Xinarianos, G., Pushpakom, S., Liloglou, T., Zhang, E., . . . Clark, R. E. (2011). Correlation of hOCT1 SNPs and clinical outcome in imatinib treated chronic myeloid leukaemia patients; functional significance of M420del and M408V. In NCRI Cancer Conference (pp. B242). Liverpool: NCRI.

Correlation of hOCT1 genetic polymorphims with the clinical outcome of chronic myeloid leukaemia patients treated with imatinib (Conference Paper)

Giannoudis, A., Wang, L., Xinarianos, G., Pushpakom, S., Liloglou, T., Zhang, E., . . . Clark, R. E. (2011). Correlation of hOCT1 genetic polymorphims with the clinical outcome of chronic myeloid leukaemia patients treated with imatinib. In European School of Haematology CML Annual Meeting (pp. P123). Estoril: ESH.

Interaction of the common hOCT1 SNPs M420del and M408V is critical in predicting clinical outcome in chronic myeloid leukaemia patients treated with imatinib (Conference Paper)

Giannoudis, A., Wang, L., Xinarianos, G., Pushpakom, S., Liloglou, T., Zhang, E., . . . Clark, R. E. (2011). Interaction of the common hOCT1 SNPs M420del and M408V is critical in predicting clinical outcome in chronic myeloid leukaemia patients treated with imatinib. In 16th Congress of the European Association of Haematology (pp. P89). London: EHA.

The ABCC3 efflux transporter can predict clinical outcome in CML patients and is an important determinant of drug failure. (Journal article)

Giannoudis, A., Davies, A., Harris, R. J., Lucas, C. M., Francis, S., Pirmohamed, M., & Clark, R. E. (2011). The ABCC3 efflux transporter can predict clinical outcome in CML patients and is an important determinant of drug failure.. Haematologica, 96, S1-S678.

2010

Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours (Conference Paper)

Muthana, M., Giannoudis, A., Scott, S. D., Mistry, R., Murdoch, C., Coffelt, S., . . . Lewis, C. E. (2010). Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours. In DRUG DISCOVERY TODAY Vol. 15 (pp. 1097-1098). doi:10.1016/j.drudis.2010.09.398

DOI: 10.1016/j.drudis.2010.09.398

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 149(3), 458-460. doi:10.1111/j.1365-2141.2009.08066.x

DOI: 10.1111/j.1365-2141.2009.08066.x

CORRELATION OF HOCT1 M420DEL SNP WITH THE CLINICAL OUTCOME OF CHRONIC MYELOID LEUKAEMIA PATIENTS TREATED WITH IMATINIB (Journal article)

Giannoudis, A., Wang, L., Xynarianos, G., Liloglou, T., Austin, G., Clark, J., . . . Clark, R. (2010). CORRELATION OF HOCT1 M420DEL SNP WITH THE CLINICAL OUTCOME OF CHRONIC MYELOID LEUKAEMIA PATIENTS TREATED WITH IMATINIB. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 341. Retrieved from https://www.webofscience.com/

Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours (Conference Paper)

Muthana, M., Giannoudis, A., Scott, S. D., Mistry, R., Murdoch, C., Georgeopolous, L., . . . Lewis, C. E. (2010). Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours. In HUMAN GENE THERAPY Vol. 21 (pp. 488). Retrieved from https://www.webofscience.com/

HOCT1 M420 DELETED TRANSCRIPT LEVELS PREDICT POOR CLINICAL OUTCOME FOR IMATINIB TREATED CML PATIENTS (Journal article)

Wang, L., Giannoudis, A., Austin, G., Liloglou, T., Xinarianos, G., Clark, J., . . . Clark, R. (2010). HOCT1 M420 DELETED TRANSCRIPT LEVELS PREDICT POOR CLINICAL OUTCOME FOR IMATINIB TREATED CML PATIENTS. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 61. Retrieved from https://www.webofscience.com/

THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML (Journal article)

Lucas, C., Harris, R. J., Giannoudis, A., & Clark, R. (2010). THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 338. Retrieved from https://www.webofscience.com/

The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia. British Journal of Haematology, 149, 158-160.

2009

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94(10), 1362-1367. doi:10.3324/haematol.2009.009134

DOI: 10.3324/haematol.2009.009134

A STUDY OF PLASMA LEVELS OF IMATINIB AND ITS BIOACTIVE METABOLITE CGP-74588 REVEALS NO CORRELATION WITH SUBSEQUENT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA (Conference Paper)

Davies, A., Hayes, A. K., Giannoudis, A., Lucas, C. M., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). A STUDY OF PLASMA LEVELS OF IMATINIB AND ITS BIOACTIVE METABOLITE CGP-74588 REVEALS NO CORRELATION WITH SUBSEQUENT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 94 (pp. 259). Retrieved from https://www.webofscience.com/

FACS assessment of pCrKL/CrKL ratio at initial diagnosis is predictive of long term treatment outcome in chronic myeloid leukaemia (CML) (Conference Paper)

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2009). FACS assessment of pCrKL/CrKL ratio at initial diagnosis is predictive of long term treatment outcome in chronic myeloid leukaemia (CML). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 145 (pp. 62). Retrieved from https://www.webofscience.com/

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters (Journal article)

Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., Harris, R. J., . . . Mountford, J. C. (2009). Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. LEUKEMIA, 23(11), 1999-2006. doi:10.1038/leu.2009.166

DOI: 10.1038/leu.2009.166

2008

Human Papilloma Virus (HPV) and Host Cellular Interactions (Journal article)

Mammas, I. N., Sourvinos, G., Giannoudis, A., & Spandidos, D. A. (2008). Human Papilloma Virus (HPV) and Host Cellular Interactions. PATHOLOGY & ONCOLOGY RESEARCH, 14(4), 345-354. doi:10.1007/s12253-008-9056-6

DOI: 10.1007/s12253-008-9056-6

Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters (Journal article)

Mountford, J., Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., . . . Clark, R. E. (2008). Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. Blood, 112(11), 3205. doi:10.1182/blood.v112.11.3205.3205

DOI: 10.1182/blood.v112.11.3205.3205

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia (Journal article)

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. BLOOD, 112(8), 3348-3354. doi:10.1182/blood-2007-10-116236

DOI: 10.1182/blood-2007-10-116236

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia (Journal article)

Clark, R. E., Davies, A., Pirmohamed, M., & Giannoudis, A. (2008). Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. LEUKEMIA & LYMPHOMA, 49(4), 639-642. doi:10.1080/10428190701858823

DOI: 10.1080/10428190701858823

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia (Journal article)

Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 83(2), 258-264. doi:10.1038/sj.clpt.6100268

DOI: 10.1038/sj.clpt.6100268

Dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression, in contrast to imatinib (Conference Paper)

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression, in contrast to imatinib. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 141 (pp. 41). Retrieved from https://www.webofscience.com/

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia (Journal article)

Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics, 83(2), 258-264. doi:10.1038/sj.clpt.6100268

DOI: 10.1038/sj.clpt.6100268

Nilotinib concentration in Cell Lines and CML CD34+Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters (Conference Paper)

Mountford, J., Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., . . . Clark, R. E. (2008). Nilotinib concentration in Cell Lines and CML CD34+Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. In BLOOD Vol. 112 (pp. 1100). Retrieved from https://www.webofscience.com/

THE HUMAN ORGANIC CATION TRANSPORTER I HAS MINIMAL IMPACT IN THE UPTAKE OF DASATINIB INTO CHRONIC MYELOID LEUKAEMIA PRIMARY CELLS AND CELL LINES (Conference Paper)

Giannoudis, A., Lucas, C. M., Davies, A., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). THE HUMAN ORGANIC CATION TRANSPORTER I HAS MINIMAL IMPACT IN THE UPTAKE OF DASATINIB INTO CHRONIC MYELOID LEUKAEMIA PRIMARY CELLS AND CELL LINES. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 93 (pp. 312). Retrieved from https://www.webofscience.com/

Unlike imatinib, nilotinib transport into chronic myeloid leukaemia cells is not dependent on hOCT1 expression (Conference Paper)

Davies, A., Giannoudis, A., Lucas, C. M., Harris, R. J., Manley, P. W., Pirmohamed, M., & Clark, R. E. (2008). Unlike imatinib, nilotinib transport into chronic myeloid leukaemia cells is not dependent on hOCT1 expression. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 141 (pp. 41-42). Retrieved from https://www.webofscience.com/

2007

Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells. (Journal article)

Davies, A., Giannoudis, A., Lucas, C. M., Harris, R. J., Manley, P. W., Pirmohamed, M., & Clark, R. E. (2007). Characterisation of Nilotinib Transport in Chronic Myeloid Leukaemia Cells.. Blood, 110(11), 2364. doi:10.1182/blood.v110.11.2364.2364

DOI: 10.1182/blood.v110.11.2364.2364

Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression (Conference Paper)

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2007). Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression. In BLOOD Vol. 110 (pp. 1013A-1014A). doi:10.1182/blood.V110.11.3458.3458

DOI: 10.1182/blood.V110.11.3458.3458

Characterisation of nilotinib transport in chronic myeloid leukaemia cells (Conference Paper)

Davies, A., Giannoudis, A., Lucas, C. M., Harris, R. J., Manley, P. W., Pirmohamed, M., & Clark, R. E. (2007). Characterisation of nilotinib transport in chronic myeloid leukaemia cells. In BLOOD Vol. 110 (pp. 698A). Retrieved from https://www.webofscience.com/

2006

Clinical and functional evidence that drug transporter expression dictates the response to imatinib in chronic myeloid leukaemia. (Conference Paper)

Wang, L., Giannoudis, A., Lane, S., Williamson, P. R., Pirmohamed, M., & Clark, R. E. (2006). Clinical and functional evidence that drug transporter expression dictates the response to imatinib in chronic myeloid leukaemia.. In BLOOD Vol. 108 (pp. 608A-609A). doi:10.1182/blood.V108.11.2145.2145

DOI: 10.1182/blood.V108.11.2145.2145

Gene therapy for prostate cancer: Current strategies and new cell-based approaches (Journal article)

MacRae, E. J., Giannoudis, A., Ryan, R., Brown, N. J., Hamdy, F. C., Maitland, N., & Lewis, C. E. (2006). Gene therapy for prostate cancer: Current strategies and new cell-based approaches. PROSTATE, 66(5), 470-494. doi:10.1002/pros.20388

DOI: 10.1002/pros.20388

Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors (Journal article)

Muthana, M., Giannoudis, A., Scott, S. D., Burke, B., Mistry, R., Hamdy, F., . . . Lewis, C. E. (2006). Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors. CANCER RESEARCH, 66(8). Retrieved from https://www.webofscience.com/

Imatinib and human organic cation transporter 1 (hOCT1): Characterisation of transport in a stably transfected myeloid cell line, and relationship of hOCT1 expression to cytogenetic response (Conference Paper)

Wang, L., Giannoudis, A., Pirmohamed, M., & Clark, R. E. (2006). Imatinib and human organic cation transporter 1 (hOCT1): Characterisation of transport in a stably transfected myeloid cell line, and relationship of hOCT1 expression to cytogenetic response. In DRUG METABOLISM REVIEWS Vol. 38 (pp. 118). Retrieved from https://www.webofscience.com/

2004

Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues (Journal article)

Murdoch, C., Giannoudis, A., & Lewis, C. E. (2004). Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. BLOOD, 104(8), 2224-2234. doi:10.1182/blood-2004-03-1109

DOI: 10.1182/blood-2004-03-1109

2003

Hypoxia-induced gene expression in human macrophages - Implications for ischemic tissues and hypoxia-regulated gene therapy (Journal article)

Burke, B., Giannoudis, A., Corke, K. P., Gill, D., Wells, M., Ziegler-Heitbrock, L., & Lewis, C. E. (2003). Hypoxia-induced gene expression in human macrophages - Implications for ischemic tissues and hypoxia-regulated gene therapy. AMERICAN JOURNAL OF PATHOLOGY, 163(4), 1233-1243. doi:10.1016/S0002-9440(10)63483-9

DOI: 10.1016/S0002-9440(10)63483-9

2001

Human papillomavirus in pterygium (Journal article)

Gallagher, M. J., Giannoudis, A., Herrington, C. S., & Hiscott, P. (2001). Human papillomavirus in pterygium. BRITISH JOURNAL OF OPHTHALMOLOGY, 85(7), 782-784. doi:10.1136/bjo.85.7.782

DOI: 10.1136/bjo.85.7.782

Variation in the E2-binding domain of HPV 16 is associated with high-grade squamous intraepithelial lesions of the cervix (Journal article)

Giannoudis, A., van Duin, M., Snijders, P. J. F., & Herrington, C. S. (2001). Variation in the E2-binding domain of HPV 16 is associated with high-grade squamous intraepithelial lesions of the cervix. BRITISH JOURNAL OF CANCER, 84(8), 1058-1063. doi:10.1054/bjoc.2001.1695

DOI: 10.1054/bjoc.2001.1695

Human papillomavirus variants and squamous neoplasia of the cervix (Journal article)

Giannoudis, A., & Herrington, C. S. (2001). Human papillomavirus variants and squamous neoplasia of the cervix. JOURNAL OF PATHOLOGY, 193(3), 295-302. Retrieved from https://www.webofscience.com/

2000

Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses (Journal article)

Giannoudis, A., & Herrington, C. S. (2000). Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. CANCER, 89(6), 1300-1307. doi:3.0.CO;2-U">10.1002/1097-0142(20000915)89:6<1300::AID-CNCR15>3.0.CO;2-U

DOI: 10.1002/1097-0142(20000915)89:6<1300::AID-CNCR15>3.0.CO;2-U

"High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa (Journal article)

Bouda, M., Gorgoulis, V. G., Kastrinakis, N. G., Giannoudis, A., Tsoli, E., Danassi-Afentaki, D., . . . Kittas, C. (2000). "High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. MODERN PATHOLOGY, 13(6), 644-653. doi:10.1038/modpathol.3880113

DOI: 10.1038/modpathol.3880113

Basal keratinocyte tetrasomy in low-grade squamous intra-epithelial lesions of the cervix is restricted to high and intermediate risk HPV infection but is not type-specific (Journal article)

Giannoudis, A., Evans, M. F., Southern, S. A., & Herrington, C. S. (2000). Basal keratinocyte tetrasomy in low-grade squamous intra-epithelial lesions of the cervix is restricted to high and intermediate risk HPV infection but is not type-specific. BRITISH JOURNAL OF CANCER, 82(2), 424-428. doi:10.1054/bjoc.1999.0937

DOI: 10.1054/bjoc.1999.0937

High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection (Journal article)

Sheard, J. D. H., Vijayanand, R., Herrington, C. S., Giannoudis, A., & Shaw, G. (2000). High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection. HISTOPATHOLOGY, 37(1), 87-88. Retrieved from https://www.webofscience.com/

High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection. (Journal article)

Sheard, J. D., Vijayanand, R., Herrington, C. S., Giannoudis, A., & Shaw, G. (2000). High-grade squamous intraepithelial neoplasia in a Bartholin's gland cyst associated with HPV 16 infection.. Histopathology, 37(1), 87-88. doi:10.1046/j.1365-2559.2000.00955-4.x

DOI: 10.1046/j.1365-2559.2000.00955-4.x

Human papilloma virus in pterygium. (Journal article)

Gallagher, M. J., Giannoudis, A., Hiscott, P., & Herrington, C. S. (2000). Human papilloma virus in pterygium.. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 41(4), S129. Retrieved from https://www.webofscience.com/

1999

p53 codon 72 arg/pro polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix (Journal article)

Giannoudis, A., Graham, D. A., Southern, S. A., & Herrington, C. S. (1999). p53 codon 72 arg/pro polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. INTERNATIONAL JOURNAL OF CANCER, 83(1), 66-69. doi:3.0.CO;2-K">10.1002/(SICI)1097-0215(19990924)83:1<66::AID-IJC13>3.0.CO;2-K

DOI: 10.1002/(SICI)1097-0215(19990924)83:1<66::AID-IJC13>3.0.CO;2-K

Disruption of cell cycle regulators by human papillomaviruses in low grade squamous intraepithelial lesions of the cervix (Conference Paper)

Giannoudis, A., & Herrington, C. S. (1999). Disruption of cell cycle regulators by human papillomaviruses in low grade squamous intraepithelial lesions of the cervix. In JOURNAL OF MEDICAL GENETICS Vol. 36 (pp. S41). Retrieved from https://www.webofscience.com/

Increased prevalence of an HPV-16 E2 mutation across the spectrum of cervical intraepithelial neoplasia. (Conference Paper)

Giannoudis, A., Graham, D. A., Southern, S. A., & Herrington, C. S. (1999). Increased prevalence of an HPV-16 E2 mutation across the spectrum of cervical intraepithelial neoplasia.. In BRITISH JOURNAL OF CANCER Vol. 80 (pp. 78). Retrieved from https://www.webofscience.com/

1998

High risk human papillomaviruses can induce numerical chromosome abnormalities in low-grade squamous intraepithelial lesions (Conference Paper)

Giannoudis, A., Southern, S. A., & Herrington, C. S. (1998). High risk human papillomaviruses can induce numerical chromosome abnormalities in low-grade squamous intraepithelial lesions. In BRITISH JOURNAL OF CANCER Vol. 78 (pp. 71). Retrieved from https://www.webofscience.com/

1995

DETECTION OF EPSTEIN-BARR-VIRUS AND HUMAN PAPILLOMAVIRUS IN NASOPHARYNGEAL CARCINOMA BY THE POLYMERASE CHAIN-REACTION TECHNIQUE (Journal article)

GIANNOUDIS, A., ERGAZAKI, M., SEGAS, J., GIOTAKIS, J., ADAMOPOULOS, G., GORGOULIS, V., & SPANDIDOS, D. A. (1995). DETECTION OF EPSTEIN-BARR-VIRUS AND HUMAN PAPILLOMAVIRUS IN NASOPHARYNGEAL CARCINOMA BY THE POLYMERASE CHAIN-REACTION TECHNIQUE. CANCER LETTERS, 89(2), 177-181. doi:10.1016/0304-3835(94)03667-8

DOI: 10.1016/0304-3835(94)03667-8

1994

DETECTION OF HSV, CMV AND EBV BY THE POLYMERASE CHAIN-REACTION TECHNIQUE IN PATIENTS WITH INFLAMMATORY EYE-DISEASES (Journal article)

ERGAZAKI, M., XINARIANOS, G., GIANNOUDIS, A., MARKOMICHELAKIS, N., TSAMPARLAKIS, J., & SPANDIDOS, D. A. (1994). DETECTION OF HSV, CMV AND EBV BY THE POLYMERASE CHAIN-REACTION TECHNIQUE IN PATIENTS WITH INFLAMMATORY EYE-DISEASES. ONCOLOGY REPORTS, 1(6), 1207-1210. Retrieved from https://www.webofscience.com/

DETECTION OF HUMAN CYTOMEGALOVIRUS AND EPSTEIN-BARR-VIRUS BY THE POLYMERASE CHAIN-REACTION IN PATIENTS WITH BETA-THALASSEMIA (Journal article)

ERGAZAKI, M., XINARIANOS, G., GIANNOUDIS, A., KOFFA, M., LILOGLOU, T., KATTAMIS, C., & SPANDIDOS, D. A. (1994). DETECTION OF HUMAN CYTOMEGALOVIRUS AND EPSTEIN-BARR-VIRUS BY THE POLYMERASE CHAIN-REACTION IN PATIENTS WITH BETA-THALASSEMIA. ONCOLOGY REPORTS, 1(4), 813-816. Retrieved from https://www.webofscience.com/

DETECTION OF THE EPSTEIN-BARR-VIRUS BY THE POLYMERASE CHAIN-REACTION IN IMMUNOSUPPRESSED AND IMMUNOCOMPROMISED PATIENTS (Journal article)

LILOGLOU, T., GIANNOUDIS, A., ERGAZAKI, M., KOFFA, M., & SPANDIDOS, D. A. (1994). DETECTION OF THE EPSTEIN-BARR-VIRUS BY THE POLYMERASE CHAIN-REACTION IN IMMUNOSUPPRESSED AND IMMUNOCOMPROMISED PATIENTS. ONCOLOGY REPORTS, 1(4), 809-811. Retrieved from https://www.webofscience.com/

THE PRESENCE OF HERPESVIRUSES IN PTERYGIUM (Journal article)

SPANDIDOS, D. A., XINARIANOS, G., ERGAZAKI, M., GIANNOUDIS, A., & TSAMPARLAKIS, J. (1994). THE PRESENCE OF HERPESVIRUSES IN PTERYGIUM. INTERNATIONAL JOURNAL OF ONCOLOGY, 5(4), 749-752. Retrieved from https://www.webofscience.com/

Publications

Selected Publications

2024

A Bioinformatic Characterisation of the Glyolytic Enzyme ENO1 as a Biomarker of Breast Cancer Progression (Preprint)

2023

ENO1 as a biomarker of breast cancer progression and metastasis – a bioinformatic approach (Preprint)

Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases (Conference Paper)

Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors (Preprint)

2022

Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression (Journal article)

The role of CPT1A as a biomarker of breast cancer progression: a bioinformatic approach (Journal article)

The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis (Conference Paper)

Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases (Conference Paper)

Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors (Conference Paper)

The Role of CPT1A as a Biomarker of Breast Cancer Progression – A Bioinformatic Analysis (Preprint)

The Role of CPT1A as a Biomarker of Breast Cancer Progression – a Bioinformatic Analysis (Preprint)

2021

Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival (Journal article)

Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases (Journal article)

Genomic Profiling Using The UltraSEEK Panel Identifies Discordancy Between Paired Primary And Breast Cancer Brain Metastases And An Association With Brain Metastasis-Free Survival (Preprint)

1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells. (Journal article)

The genomic landscape of breast cancer brain metastases: a systematic review. (Journal article)

2020

Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer (Journal article)

A systematic review of the receptor status and genomic landscape of breast cancer brain metastases (Conference Paper)

The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer (Conference Paper)

UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis (Conference Paper)

2019

A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival (Journal article)

Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer (Conference Paper)

2018

Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process (Journal article)

2017

Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases (Conference Paper)

2016

A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer (Conference Paper)

2015

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib (Journal article)

C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia (Journal article)

2014

Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia (Journal article)

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia (Journal article)

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer (Journal article)

Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia (Journal article)

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer (Journal article)

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia (Journal article)

2013

Transport of gabapentin by LAT1 (SLC7A5) (Journal article)

Transport of gabapentin by LAT1 (SLC7A5) (Journal article)

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia (Journal article)

10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML) (Conference Paper)

10058-f4 a small molecule c-myc inhibitor decreases CIP2A and reduces BCR-ABL-1 tyrosine kinase activity in chronic myeloid leukaemia (Journal article)

TRANSCRIPT LEVELS AND COPY NUMBER VARIATION OF THE ABCC3 EFFLUX TRANSPORTER CAN PREDICT CLINICAL OUTCOME IN IMATINIB-TREATED CHRONIC MYELOID LEUKAEMIA PATIENTS (Conference Paper)

The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia (Journal article)

The hOCT1 substrate metformin does not alter imatinib, dasatinib or nilotinib uptake into CML cells at clinically relevant concentrations (Journal article)

Transcript levels and copy number variation of the ABCC3 efflux transporter can predict clinical outcome in imatinib-treated chronic myeloid leukaemia patients (Journal article)

of gabapentin by LAT1 (SLC7A5) (Journal article)

2012

Lamotrigine is a substrate for OCT1 in brain endothelial cells (Journal article)

DUAL GSTT1 AND GSTM1 GENE DELETIONS INCREASE THE RISK OF IMATINIB FAILURE IN CHRONIC MYELOID LEUKAEMIA (CML) (Conference Paper)

Dual GSTT1 and GSTM1 gene deletions increase the risk of imatinib failure in chronic myeloid leukaemia (Journal article)

IMATINIB, BUT NOT NILOTINIB, IS ACTIVELY TRANSPORTED BY SLCO1A2 IN CHRONIC MYELOID LEUKAEMIA CELLS (Conference Paper)

Imatinib, but not nilotinib, is actively transported by SLCO1A2 in chronic myeloid leukaemia cells (Journal article)

Lamotrigine is a substrate for OCT1 in brain endothelial cells (Journal article)

Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells (Journal article)

Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia (Journal article)

2011

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression (Journal article)

Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors (Journal article)

Correlation of hOCT1 SNPs and clinical outcome in imatinib treated chronic myeloid leukaemia patients; functional significance of M420del and M408V (Conference Paper)

Correlation of hOCT1 genetic polymorphims with the clinical outcome of chronic myeloid leukaemia patients treated with imatinib (Conference Paper)

Interaction of the common hOCT1 SNPs M420del and M408V is critical in predicting clinical outcome in chronic myeloid leukaemia patients treated with imatinib (Conference Paper)

The ABCC3 efflux transporter can predict clinical outcome in CML patients and is an important determinant of drug failure. (Journal article)

2010

Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours (Conference Paper)

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia (Journal article)

CORRELATION OF HOCT1 M420DEL SNP WITH THE CLINICAL OUTCOME OF CHRONIC MYELOID LEUKAEMIA PATIENTS TREATED WITH IMATINIB (Journal article)

Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours (Conference Paper)

HOCT1 M420 DELETED TRANSCRIPT LEVELS PREDICT POOR CLINICAL OUTCOME FOR IMATINIB TREATED CML PATIENTS (Journal article)

THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML (Journal article)